Yahoo Web Search

Search results

  1. Feb 17, 2022 · On an adjusted basis, 2021 net income attributable to Baxter totaled $1.8 billion, or $3.61 per diluted share, an increase of 17% compared to the prior-year period. Adjusted results for full-year 2021 include a contribution to earnings of $0.08 per diluted share from Hillrom.

  2. Feb 9, 2023 · The accompanying schedules include additional details on sales performance by product categories and segments. For full-year 2022, net income (loss) attributable to Baxter totaled ($2.4 billion), or ($4.83) per diluted share on a U.S. GAAP basis.

  3. Apr 28, 2022 · For full-year 2022: Baxter now expects U.S. GAAP earnings of $2.35 to $2.43 per diluted share and adjusted earnings, before special items, of $4.12 to $4.20 per diluted share. The company expects sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant currency basis and approximately 3% on an operational basis.

  4. Feb 17, 2022 · Fourth quarter adjusted earnings per share were $1.04, up 30% year-over-year. Hillrom contributed $212 million in sales and $0.08 of adjusted earnings per share in the quarter. For full year...

  5. 2022 Financial Outlook For full-year 2022: Baxter now expects U.S. GAAP earnings of $2.35 to $2.43 per diluted share and adjusted earnings, before special items, of $4.12 to $4.20 per diluted share. The company expects sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant

  6. Feb 21, 2024 · Baxter is an established market leader in big pharma and medical supplies, with expected EPS growth and declining debt. Learn why BAX stock is a Buy.

  7. People also ask

  8. Baxter net income for the twelve months ending June 30, 2024 was $2.476B, a 186.79% decline year-over-year. Baxter annual net income for 2023 was $2.656B, a 209.17% decline from 2022. Baxter annual net income for 2022 was $-2.433B, a 289.49% decline from 2021.

  1. People also search for